Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - Secondary Analysis of Databases

Université de Montréal

$100,000.00

Asthma medications during pregnancy and the risk of hypertensive disorders of pregnancy and gestational diabetes

EF 2011-12

Résumé
Asthma is an increasingly common serious medical condition during pregnancy. According to contemporary guidelines, it is safer for pregnant women with asthma to be treated with asthma medications than it is for them to have asthma symptoms and exacerbations, that is uncontrolled asthma. However, we do not know with certainty whether the asthma medications used during pregnancy to prevent asthma manifestations, namely inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) can have negative effects on the mother, such as hypertension during pregnancy and diabetes during pregnancy. Our study will determine: i) the risk of developing diabetes during pregnancy among pregnant asthmatic women using high doses of ICS compared to those not using them; and ii) the risk of developing diabetes during pregnancy and hypertension during pregnancy among pregnant asthmatic women using LABA compared to those not using them. Knowing whether or not specific medications increase the risk of these adverse maternal outcomes is absolutely necessary for women and clinicians to accurately estimate the benefit/risk ratio of treatment alternatives to choose the best treatment for each woman and do their best to avoid adverse outcomes. By reducing the risk of adverse effects of medications taken during pregnancy, we do not just improve the health of the pregnant woman and the fetus, we also improve the capacity of the mother, the primary care giver, to adequately take care of her baby during this critical period of life that is the months following birth.
Programme
Operating Grant - Secondary Analysis of Databases
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
231284
Name
Blais Lucie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Clinical
Prcname2
Secondary Analysis of Databases
Projecttitle
Asthma medications during pregnancy and the risk of hypertensive disorders of pregnancy and gestational diabetes
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Secondary Analysis of Databases
Keyworddelim
Administrative Databases; Asthma Medications; Cohort Study; Gestationa Diabetes; Hypertensive Disorders Of Pregnancy; Pregnancy
Abstract
Asthma is an increasingly common serious medical condition during pregnancy. According to contemporary guidelines, it is safer for pregnant women with asthma to be treated with asthma medications than it is for them to have asthma symptoms and exacerbations, that is uncontrolled asthma. However, we do not know with certainty whether the asthma medications used during pregnancy to prevent asthma manifestations, namely inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) can have negative effects on the mother, such as hypertension during pregnancy and diabetes during pregnancy. Our study will determine: i) the risk of developing diabetes during pregnancy among pregnant asthmatic women using high doses of ICS compared to those not using them; and ii) the risk of developing diabetes during pregnancy and hypertension during pregnancy among pregnant asthmatic women using LABA compared to those not using them. Knowing whether or not specific medications increase the risk of these adverse maternal outcomes is absolutely necessary for women and clinicians to accurately estimate the benefit/risk ratio of treatment alternatives to choose the best treatment for each woman and do their best to avoid adverse outcomes. By reducing the risk of adverse effects of medications taken during pregnancy, we do not just improve the health of the pregnant woman and the fetus, we also improve the capacity of the mother, the primary care giver, to adequately take care of her baby during this critical period of life that is the months following birth.
Competitiondate
201104
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Blais, Lucie
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $100,000~ $0~